Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)

M. Campos (Miami, United States of America), P. Geraghty (New York, United States of America), G. Holt (Miami, United States of America), E. Donna (Miami, United States of America), E. Mendes (Miami, United States of America), L. Escobar (Miami, United States of America), L. Luna (Miami, United States of America), R. Stockley (Birmingham, United Kingdom)

Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Session: COPD phenotypes: a1 antitrypsin deficiency and beyond
Session type: Poster Discussion
Number: 571
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Campos (Miami, United States of America), P. Geraghty (New York, United States of America), G. Holt (Miami, United States of America), E. Donna (Miami, United States of America), E. Mendes (Miami, United States of America), L. Escobar (Miami, United States of America), L. Luna (Miami, United States of America), R. Stockley (Birmingham, United Kingdom). Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD). 571

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: